Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with low response rates and survival rarely exceeding six months. There are no clearly establ...